Official Title
Innovative Support for Patients with SARS-COV2 Infections (COVID-19) Registry (INSPIRE)
Brief Summary

The Innovative Support for Patients with SARS COV-2 Infections Registry (INSPIRE) studyis a CDC-funded COVID-19 project to understand the long-term health outcomes in recentlytested adults, both negative and positive, who have suspected COVID symptoms at the timeof their test. Participants will complete short online surveys every 3 months for 18months, share information about their health using a secure web-based platform, and arecompensated for their time.

Detailed Description

This study will use a digital platform to longitudinally track comprehensive information
including patient self-report as well as data that describe the process and outcome of
care in the electronic medical record (EMR) of a large representative sample of patients
under investigation for SARSCOV2. The objective is to generate knowledge rapidly using
digital tools and collaborative sciences to produce real-time data, analysis, and
reporting compared to more traditional approaches. An additional goal is to promote an
open science approach whereby scientists, with proper approvals and in line with the
permissions granted by the participants, have the opportunity to work with data in ways
that protect individual privacy but promote rapid dissemination and implementation of
knowledge.

Active, not recruiting
COVID19
ME/CFS
SARS COV2
Novel Coronavirus Infection
Neurocognitive Disorders
Cardiovascular Diseases
Eligibility Criteria

INCLUSION CRITERIA

1. Fluent in English or Spanish;

2. Age 18 and over;

3. Self-reported symptoms suggestive of acute SARSCOV2 infection;

4. Under investigation for SARSCOV2 (defined as a patient who has received any
screening or diagnostic test used to detect the presence of COVID19 including any
FDA approved or authorized molecular or antigen-based assay) within the last 42
days.

EXCLUSION CRITERIA

1. Unable to provide informed consent;

2. Study team unable to confirm result of diagnostic test for SARSCOV2;

3. Does not have access to a hand-held device or computer that would allow for digital
participation in the study;

4. Individuals who are prisoners while participating in the study.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

UCLA
Los Angeles, California, United States

UCSF
San Francisco, California, United States

Yale
New Haven, Connecticut, United States

Rush University Medical Center
Chicago, Illinois, United States

Thomas Jefferson University
Philadelphia, Pennsylvania, United States

University of Texas Southwestern
Dallas, Texas, United States

University of Texas Health Science Center at Houston
Houston, Texas, United States

University of Washington
Seattle, Washington, United States

Rush University Medical Center
NCT Number
MeSH Terms
Infections
Communicable Diseases
COVID-19
Coronavirus Infections
Cardiovascular Diseases
Neurocognitive Disorders